155 related articles for article (PubMed ID: 7081976)
1. High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme.
Cisani G; Varaldo PE; Grazi G; Soro O
Antimicrob Agents Chemother; 1982 Apr; 21(4):531-5. PubMed ID: 7081976
[TBL] [Abstract][Full Text] [Related]
2. Detection of Staphylococcus aureus with a fluorescence in situ hybridization that does not require lysostaphin.
Lawson TS; Connally RE; Iredell JR; Vemulpad S; Piper JA
J Clin Lab Anal; 2011; 25(2):142-7. PubMed ID: 21438009
[TBL] [Abstract][Full Text] [Related]
3. Host Cationic Antimicrobial Molecules Inhibit S. aureus Exotoxin Production.
Schlievert PM; Kilgore SH; Beck LA; Yoshida T; Klingelhutz AJ; Leung DYM
mSphere; 2023 Feb; 8(1):e0057622. PubMed ID: 36598227
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China.
Yang XY; Li CR; Lou RH; Wang YM; Zhang WX; Chen HZ; Huang QS; Han YX; Jiang JD; You XF
J Med Microbiol; 2007 Jan; 56(Pt 1):71-76. PubMed ID: 17172520
[TBL] [Abstract][Full Text] [Related]
5. [Antiseptic effect of compound lysostaphin disinfectant and its preventive effect on infection of artificial dermis after graft on full-thickness skin defect wound in rats].
Jin J; Zhou H; Cui ZC; Wang L; Luo PF; Ji SZ; Hu XY; Ma B; Wang GY; Zhu SH; Xia ZF
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):225-232. PubMed ID: 29690741
[No Abstract] [Full Text] [Related]
6. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus.
Polak J; Della Latta P; Blackburn P
Diagn Microbiol Infect Dis; 1993; 17(4):265-70. PubMed ID: 8112040
[TBL] [Abstract][Full Text] [Related]
7. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
Kusuma CM; Kokai-Kun JF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3256-63. PubMed ID: 16048934
[TBL] [Abstract][Full Text] [Related]
8. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin.
Graham S; Coote PJ
J Antimicrob Chemother; 2007 Apr; 59(4):759-62. PubMed ID: 17324959
[TBL] [Abstract][Full Text] [Related]
9. Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis.
Kiri N; Archer G; Climo MW
Antimicrob Agents Chemother; 2002 Jun; 46(6):2017-20. PubMed ID: 12019130
[TBL] [Abstract][Full Text] [Related]
10. Rapid identification of Staphylococcus aureus by using lysostaphin sensitivity.
Severance PJ; Kauffman CA; Sheagren JN
J Clin Microbiol; 1980 Jun; 11(6):724-7. PubMed ID: 7430338
[TBL] [Abstract][Full Text] [Related]
11. Lysostaphin disk test for routine presumptive identification of staphylococci.
Poutrel B; Caffin JP
J Clin Microbiol; 1981 Jun; 13(6):1023-5. PubMed ID: 7019233
[TBL] [Abstract][Full Text] [Related]
12. Effect of BiTek agar on lysostaphin susceptibility of staphylococci.
Langlois BE; Dawson K; Akers K
J Clin Microbiol; 1990 Nov; 28(11):2568-9. PubMed ID: 2254432
[TBL] [Abstract][Full Text] [Related]
13. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces.
Wu JA; Kusuma C; Mond JJ; Kokai-Kun JF
Antimicrob Agents Chemother; 2003 Nov; 47(11):3407-14. PubMed ID: 14576095
[TBL] [Abstract][Full Text] [Related]
14. [Cloning of lysozyme and lysostaphin genes of Staphylococcus aureus and their expression in Bacillus subtilis cells].
Zhdanova LV; Romanova IuM; Bondarenko VM; Konstantinova GE; Shevelev AB
Zh Mikrobiol Epidemiol Immunobiol; 2001; (4):3-6. PubMed ID: 11569257
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
Desbois AP; Gemmell CG; Coote PJ
Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
[TBL] [Abstract][Full Text] [Related]
16. COMPARATIVE IN VITRO ACTIVITIES OF LYSOSTAPHIN AND OTHER ANTISTAPHYLOCOCCAL ANTIBIOTICS ON CLINICAL ISOLATES OF STAPHYLOCOCCUS AUREUS.
HARRISON EF; CROPP CB
Appl Microbiol; 1965 Mar; 13(2):212-5. PubMed ID: 14325881
[TBL] [Abstract][Full Text] [Related]
17. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
Becker SC; Foster-Frey J; Donovan DM
FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal synergy of lysostaphin in combination with antimicrobial peptides.
Desbois AP; Coote PJ
Eur J Clin Microbiol Infect Dis; 2011 Aug; 30(8):1015-21. PubMed ID: 21311938
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the lysostaphin-susceptibility test for the classification of staphylococci.
Heddaeus H; Heczko PB; Pulverer G
J Med Microbiol; 1979 Feb; 12(1):9-15. PubMed ID: 430548
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic applications of lysostaphin against Staphylococcus aureus.
Jayakumar J; Kumar VA; Biswas L; Biswas R
J Appl Microbiol; 2021 Sep; 131(3):1072-1082. PubMed ID: 33382154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
